Skip to main content
GCTK
NASDAQ Industrial Applications And Services

Glucotrack Converts $988K Debt to Equity, Issuing 1.3 Million Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.815
Mkt Cap
$1.66M
52W Low
$0.619
52W High
$15.9
52W Position info
32% above low
Off High info
95% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

GCTK sits 32% above its 52-week low of $0.619.

Summary

Glucotrack, Inc. executed an Exchange Agreement to convert $988,000 of existing promissory notes into 1,300,000 shares of common stock, significantly reducing debt but causing substantial dilution.


Key Events · Financing and Capital Events · GCTK

  • Debt-to-Equity Conversion

    Glucotrack entered an Exchange Agreement on April 29, 2026, to convert $988,000 of an existing promissory note into equity.

  • Significant Equity Issuance

    1,300,000 shares of common stock were issued to an investor in exchange for the partitioned note, with an implied conversion price of $0.76 per share.

  • Balance Sheet Restructuring

    This transaction reduces the company's financial obligations, improving its debt profile, which is crucial for a micro-cap company.

  • Investor Presentation Furnished

    An updated investor presentation was furnished, providing details on the company's product development and clinical data, including a recent peer-reviewed study.


Analysis · GCTK · Industrial Applications And Services

This debt-to-equity conversion is a critical financial maneuver for Glucotrack, Inc., substantially reducing its outstanding debt by nearly $1 million. While this move improves the company's balance sheet and provides a necessary runway for a micro-cap entity, it also results in significant dilution for existing shareholders, with 1.3 million new shares issued. The implied conversion price of $0.76 per share is slightly below the current market price. Investors should monitor the impact of this balance sheet restructuring on the company's financial stability and future capital needs. Additionally, the company furnished an updated investor presentation, which provides further context on its product development and clinical progress, following earlier news of a peer-reviewed study.

How filings like this one have moved

In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GCTK was trading at $0.82 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.62 to $15.90. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GCTK - Latest Insights

GCTK
Oct 14, 2026, 10:02 AM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $1.05
Real-time Price: $0.7325 info
Change: -$0.3175 (-30%) info
Market Cap: $738.062K info
GCTK
Oct 13, 2026, 9:45 PM EDT
Filing Type: S-1/A
Importance Score:
8
Price at Filing: $1.11
Real-time Price: $0.7325 info
Change: -$0.3775 (-34%) info
Market Cap: $738.062K info
GCTK
Sep 28, 2026, 5:29 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.78
Real-time Price: $0.7325 info
Change: -$1.05 (-59%) info
Market Cap: $738.062K info
GCTK
Sep 24, 2026, 5:25 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $0.7325 info
Change: -$1.92 (-72%) info
Market Cap: $738.062K info
GCTK
Sep 24, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $0.7325 info
Change: -$1.92 (-72%) info
Market Cap: $738.062K info